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Abstract 
Background: Ovarian cancer is a common type of gynecological malignancies, and is the fifth leading cause of 
cancer-related death in women in the United States. MiR-429 and KIAA0101 have been found to be involved in several 
human malignancies, respectively. However, the role of miR-429 and KIAA0101, and the correlation between them 
during development of epithelial ovarian cancer (EOC) remain to be investigated.
Methods: The expression of KIAA0101 in EOC tissues and cells was measured by Quantitative real-time PCR, western 
blot, and immunochemistry. Cell proliferation assay, colony formation assay, and transwell assay was performed to 
assess the role of miR-429 and KIAA0101 in regulation of proliferation, migration, and chemoresistance of EOC cells. 
Luciferase assay was used to test the Wnt/β-catenin signaling activity in response to depletion of KIAA0101 and over-
expression of miR-429.
Results: We found that KIAA0101 was upregulated in metastatic EOC tissues, compared to primary EOC tissues, and 
KIAA0101 was required for the migration activity and chemoresistance of EOC cells by enhancing Wnt/β-catenin sign-
aling. Furthermore, we revealed KIAA0101 is direct target of miR-429. Similar to knockdown of KIAA0101, overexpres-
sion of miR-429 reduced invasion and chemoresistance of EOC cells. Co-transfection of KIAA0101 partially abrogates 
the inhibitory effects on invasion and chemoresistance in EOC cells.
Conclusions: KIAA0101, a target gene of miR-429, was upregulated in the metastatic EOC tissues, and enhanced the 
migration activity and chemoresistance of EOC cells. Both miR-429 and KIAA0101 may represent the potential thera-
peutic targets of EOC.
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Background
Ovarian cancer is the one of the most lethal of gyneco-
logic cancers, including epithelial ovarian cancer (EOC) 
[1, 2]. EOC is a common type of gynecological malig-
nancy that accounts for the majority of gynecologic 
cancer-related, mainly because of the highly metastatic 
capacity of EOC cells [3]. During the progression of EOC, 
a portion of tumor cells may slough out from the primary 
sites, and subsequently spread throughout the perito-
neal cavity [4, 5]. Due to the lack of reliable diagnostic 
biomarkers and the development of chemoresistance, the 
diagnosis and treatment of EOC remains to be a serious 
public challenge [6, 7]. Hence, it is crucial to improve our 
understanding in the underlying mechanisms that pro-
motes metastasis and chemoresistance of EOC.
microRNAs (miRNAs) is a class of endogenous small 
non-coding RNAs, which are capable to post-transcrip-
tionally modulate gene expression [8, 9]. In recent years, 
accumulating evidence has demonstrated that miRNAs 
are involved in cancer development by acting as onco-
genes or tumor suppressors [9, 10]. MiR-429, a member 
of the miR-200 family of miRNAs, has been reported 
to inhibit invasion in gastric cancer [11], colorectal car-
cinoma [12], breast cancer [13], and oral squamous cell 
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carcinoma [14], indicating a tumor suppressing effect of 
miR-429. However, higher expression of miR-429 was 
shown to be significantly correlated with a poor progno-
sis of patients with serous ovarian carcinoma (SOC) [15, 
16]. These findings revealed different effects of miR-429 
on cancer progression that are initiated from different 
tissues.
Proliferating cell nuclear antigen (PCNA) is an essential 
protein for DNA replication and repair, and high expres-
sion of PCNA is considered as a hallmark of cell prolifer-
ation, which is associated with high cell proliferation rate 
in cancers, such as prostate cancer and ovarian cancer 
[17]. KIAA0101, also known as p15PAF (PCNA-associate 
factor), contains a conserved PCNA-binding motif, and 
elevated KIAA0101 has been recently identified as an 
oncogene, and a potential biomarker for recurrence and 
poor prognosis in patients with lung cancer [18], esopha-
geal cancer [19], and gastric cancer [20], respectively. 
Furthermore, overexpression of KIAA0101 during devel-
opment of adrenal cancer was found to promote growth 
and invasion of tumor cells [21]. In addition, upregula-
tion of KIAA0101 in patients with esophageal cancer was 
associated with progression and chemoresistance [19]. 
However, the role of KIAA0101 in regulation of devel-
opment of EOC remains largely unknown. Specifically, 
the relationship between miR-429 and KIAA0101 is still 
unclear.
In this study, we examined the expression levels of 
miR-429 and KIAA0101 in primary and metastatic 
EOC tissues, and investigated the role of miR-429 and 
KIAA0101 in regulation of invasion and chemoresistance 
of EOCs. We found that miR-429 directly targeted the 3′ 
UTR of KIAA0101 transcripts, and negatively regulated 
the expression of KIAA0101. By using siRNA targeting 
KIAA0101, we demonstrated KIAA0101 is required for 
the invasion and chemoresistance to Cisplatin of EOC 
cells via promoting the translocation of β-catenin to 
nucleus. Finally, while overexpression of miR-429 exhib-
ited an inhibition on invasion and chemoresistance, co-
transfection of KIAA0101, at least in part, restored the 
invasion and chemoresistance of EOC cells.
Methods
Human samples
Tissues were collected from patients who underwent sur-
gery at the Department of Obstetrics and Gynecology 
of Harbin Medical University Cancer Hospital between 
2012 and 2013, including 40 epithelial EOC tissues and 
20 normal epithelial ovarian tissue sections. None of 
the patients were treated with chemotherapy or radio-
therapy before they were subjected to operation. The 
histopathological diagnoses were performed according to 
the World Health Organization criteria. All fresh speci-
mens were stored at −80  °C for further use. This study 
was approved by the Medical Ethics Committee of Har-
bin Medical University Cancer Hospital and all patients 
were provided informed consent.
Immunohistochemistry (IHC)
Tumor samples were fixed in 4 % formaldehyde, embed-
ded in paraffin wax, and then cut into 5  µM sections. 
Samples were de-paraffinized in xylene and rehydrated. 
After blocking endogenous peroxidase and perform-
ing antigen retrieval, tissue slides were blocked in goat 
serum for 30 min and incubated with antibodies against 
KIAA0101 (1:100 dilution, Santa Cruz, Santa Cruz, CA, 
USA) overnight at 4 °C, followed by biotinylated second-
ary antibody (Santa Cruz) for 30 min. Staining was per-
formed in parallel using a Vectastain ABC kit (Vector 
Laboratories, Burlingame, CA, USA).
Cancer cell lines and culture
The human EOC cell lines SKOV3 and COV644 were 
supplied by China Center for Type Culture Collection 
(CCTCC). EOC cells were cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM; Gibco-BRL, Gaithersburg, 
MD, USA), supplemented with 10 % fetal bovine serum 
and antibiotics (Gibco). All cells were incubated at 37 °C 
under a humidified atmosphere containing 5 % CO2.
Quantitative real‑time PCR (qRT‑PCR)
qRT-PCR was performed as previously described [22]. 
Briefly, total RNA was extracted using Trizol reagent 
(Invitrogen, Carlsbad, CA, USA). qRT-PCR analyses for 
mRNA of KIAA0101 were performed by using QIA-
GEN OneStep RT-PCR kits (Qiagen, Valencia, CA, 
USA). The mRNA level of β-actin was measured as 
an internal control. To measure miR-429 expression, 
total RNA was polyadenylated and reverse transcribed 
using TaqMan MicroRNA Reverse Transcription Kit 
and TaqMan miRNA assay (Applied Biosystems, Foster 
City, CA, USA) according to the manufacturer’s instruc-
tions. The expression of U6 small nuclear RNA was 
used as the internal control. RT-PCR was performed in 
triplicates. Relative expression of the tested genes was 
calculated and normalized using the 2−ΔΔCt method. 
Primers were as follows: KIAA0101 forward, 5′TCCTG 
AAGAGGCAGGAAGCAG T 3′, reverse, 5′ TTGTG 
TGATCAGGTTGCAAAGGA 3′; β-actin forward, 5′ T 
GACGGGGTCACCCACACTGTGCCCATCTA3 ′ , 
reverse, 5′ CTAGAAGCATTTGCGGTGGACGATGG 
AGGG 3′.
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Transfection and luciferase assay
All oligonucleotides were transfected into EOC cells at a 
final concentration of 50  nM using HiPerFect transfec-
tion reagent according to the product manual (Qiagen). 
The wild type full-length 3′UTR of KIAA0101 gene con-
taining the putative miR-429 biding sites was amplified 
by PCR and was inserted into the psiCHECK2 vector 
(Promega, Madison, WI, USA). The mutant KIAA0101 
3′-UTR was generated from the KIAA0101 3′-UTR 
using the QuikChange® Multi Site-Directed Mutagen-
esis kit (Stratagene, La Jolla, CA, USA). The coding 
sequences of KIAA0101 were generated by PCR and 
cloned into pCDNA3.1 (+) vector (Invitrogen) to gen-
erate pCDNA3.1-KIAA0101. The luciferase reporter 
vector (KIAA0101 3′UTR and TOP flash), pCDNA3.1-
KIAA0101 and Renilla plasmid were all transfected using 
Lipofectamine LTX according to the manufacturer’s 
instructions.
Cells were seeded in triplicate in 24-well plates  1  day 
before transfection for the luciferase assay. 48  h after 
transfection, the cells were harvested and lysed, and 
the luciferase activity assayed using the dual-luciferase 
assay kit (Promega). Normalized luciferase activity was 
reported as luciferase activity/Renilla luciferase activity. 
Three independent experiments were performed.
Cell proliferation assay
The cell growth rate with Cisplatin treatment were deter-
mined by MTT assay (Promega). Briefly, at 48  h after 
transfection, the cells were seeded into 96-well plates at 
5000 per well in a final volume of 100  μl with different 
concentration of Cisplatin (0, 4, 8, 16, 32 and 64  µM). 
Then at 48  h, 25  µl of MTT stock solution was added 
to each well and incubated for 4 h. The absorbance was 
measured at 570  nM. The assays were performed in 
triplicate.
Colony formation assay
The transfected EOC cells were seeded in 6-well plates 
(400 cells per well) and cultured for 10 days with different 
concentrations of Cisplatin (0, 8 and 32  µM). The cells 
were fixed with 10  % formalin, and stained with 0.5  % 
crystal violet (Sigma, St. Louis, MO, USA). The assay was 
performed in five replicates.
Transwell migration and invasion assays
In vitro cell migration and invasion assays were per-
formed using 24-well Transwell chambers (8-µM pores, 
BD Biosciences, San Jose, CA, USA). The transfected 
EOC cells (5 × 104 cells per well) were cultured in the top 
chamber with 100 µl medium containing 1 % FBS. 500 μl 
complete media with 10 % FBS was added into the lower 
chamber. After 24 h of cultivation, the medium from the 
chamber and the Transwell were removed, and the cham-
ber was gently wiped with a cotton swab. The migrated 
cells were fixed in 4  % paraformaldehyde, and stained 
with crystal violet solution. Six fields were randomly 
selected and counted. The procedure for the cell inva-
sion assay was similar to the cell migration assay, except 
that the Transwell membranes were pre-coated with 
Matrigel (BD Biosciences). The assays were performed in 
triplicate.
Western blot
Western blot was performed as described previously 
[23]. Briefly, Total protein was extracted by RIPA buffer. 
Nuclear protein was extracted using nuclear extracted 
kit (Beyotime, Beijing, China). The total extracts were 
separated using 10  % SDS–polyacrylamide gels and 
transferred onto polyvinylidene difluoride (PVDF) mem-
branes (Bio-Rad, Hercules, CA, USA). The membranes 
were probed with a primary antibody against human 
KIAA0101, β-catenin, Axin2, c-myc, Histone or β-actin 
(Santa Cruz), respectively. After several washes with 
TBST, the membranes were incubated with (HRP)-con-
jugated secondary antibody (Santa Cruz). Bound anti-
body was detected using the Supersignal West Pico ECL 
chemiluminescence kit (Thermo scientific, Rockford, IL, 
USA).
Statistical analysis
Statistical analyses were performed by SPSS Windows 
version 19. Data was expressed as mean  ±  SD of the 
experiments performed in triplicate. One-Way ANOVA 
was performed to determine the significance of differ-
ence among groups. Differences were considered signifi-
cant at *p < 0.05, **p < 0.01 and ***p < 0.001.
Results
The expression of KIAA0101 is elevated in EOC samples
In order to determine the clinical relevance of KIAA0101 
in human EOC development, we analyzed the expres-
sion levels of KIAA0101 in 40 primary EOC tumor tis-
sues and 20 normal ovarian epithelial tissues. We found 
that compared to those in normal ovarian epithelial tis-
sues, the levels of KIAA0101 expression were signifi-
cantly higher in EOC tissues (Fig. 1a, p < 0.001). Cancer 
cells were found metastasized to the greater omentum in 
two of those EOC patients. Furthermore, we performed 
western blot to test KIAA0101 protein expression in 
primary EOC tissues and two EOC tissues with greater 
omentum, and found KIAA0101 was significantly higher 
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in metastatic EOC tissues (Fig.  1b). Consistently, IHC 
results revealed that KIAA0101 staining was stronger in 
greater omentum metastatic EOC tissues compared to 
paired primary cancer tissues (Fig.  1c). Taken together, 
these data indicated that KIAA0101 was up-regulated in 
EOC tissues, and may play an important role in promot-
ing EOC metastasis.
Knockdown of KIAA0101 inhibits EOC cell migration 
and invasion
Next, we sought to determine whether downregulation 
of KIAA0101 expression could affect the metastasis of 
EOC cells. We transfected KIAA0101 siRNA or control 
siRNA into SKOV3 and COV644 cells, and confirmed the 
downregulated expression of KIAA0101 in SKOV3 and 
COV644 cells after 48  h (Fig.  2a). We performed west-
ern blot to assess the expression of EMT markers, E-cad-
herin and N-cadherin. As shown in Fig. 2b, knockdown 
of KIAA0101 significantly increased E-cadherin and 
decreased N-cadherin expression. Furthermore, we dis-
covered that in both cell lines, knockdown of KIAA0101 
resulted in a significantly decrease in migration and inva-
sion compared to those transfected with control siRNA, 
as determined by Transwell assays (Fig.  2c, d). Col-
lectively, these results indicate that KIAA0101 may be 
required for the metastatic ability of EOC cells.
Knockdown of KIAA0101 inhibits EOC cell chemoresistance
KIAA0101 has been reported involving in drug resist-
ance in esophageal and hepatocellular cancers [19, 24]. 
To explore whether KIAA0101 regulates EOC chemore-
sistance, we first treated SKOV3 and COV644 cells with 
8  µM Cisplatin for 24  h and then changed to complete 
medium without Cisplatin for 48  h. KIAA0101 expres-
sion were examined at different time points. The results 
revealed that KIAA0101 was significantly upregulated 
after 6 h of Cisplatin treatment (Fig. 3a). We next treated 
EOC cells with different concentration of Cisplatin and 
performed MTT assays to examine cell growth rate. As 
shown in Fig.  3b, knockdown of KIAA0101 resulted in 
EOC cells more sensitive to Cisplatin treatment.
Additionally, colony formation assays demonstrated 
that knockdown of KIAA0101 significantly inhibited 
EOC cell growth with Cisplatin treatment (Fig. 3c). Col-
lectively, these results indicated that KIAA0101 is essen-
tial for the resistance of EOC cell to Cisplatin.
Fig. 1 Upregulation of KIAA0101 in ovarian cancer samples. a Relative mRNA levels of KIAA0101 was determined by qRT-PCR in 40 EOC tissues 
and in 20 normal epithelial tissues samples. P < 0.001. b KIAA0101 expression was determined by western blot in primary and greater omentum 
metastatic EOC tissues from two patients. c KIAA0101 expression was determined by IHC in primary and greater omentum metastatic EOC tissues. 
Scale bar 100 µM
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KIAA0101 regulates Wnt/β‑catenin signaling in EOC cells
KIAA0101 regulates Wnt/β-catenin signaling in colon 
cancer cells [25]. In order to elucidate the molecular 
mechanisms of KIAA0101′s function in EOC, TOP flash 
reporter luciferase assays revealed the Wnt/β-catenin 
signaling activity was inhibited by depletion of KIAA0101 
(Fig.  4a). We then examined β-catenin levels in the 
nucleus and cytoplasm of SKOV3 and COV644 cells in 
response to KIAA0101 silencing. The result showed 
that depletion of KIAA0101 inhibited β-catenin nuclear 
translocation (Fig. 4b). Furthermore, we performed qRT-
PCR and western blot to investigate the expression of 
Wnt/β-catenin signaling downstream genes, Axin2 and 
c-myc. Consistently, the expression of Axin2 and c-myc 
Fig. 2 Knockdown of KIAA0101 inhibits ovarian cancer cell migration and invasion. a Expression levels of KIAA0101 was determined by western 
blot in SKOV3 and COV644 cells transfected with KIAA0101 siRNA (siR-KIAA0101) or control siRNA (siR-Control). b Western blot analysis of E-cadherin 
and N-cadherin in SKOV3 and COV644 cells transfected with siR-KIAA0101 or siR-Control. c Migration and d Invasion assays in SKOV3 and COV644 
cells transfected with siR-KIAA0101 or siR-Control. **p < 0.01, ***p < 0.001 compared with siR-Control transfected cells
Page 6 of 11Chen et al. Cancer Cell Int  (2016) 16:74 
was decreased after knockdown of KIAA0101 (Fig.  4c, 
d). These findings provided the evidences that KIAA0101 
regulates Wnt/β-catenin signaling.
KIAA0101 is targeted by miR‑429
We employed the bioinformatic Target Scan tools to 
predict the miRNA targeting KIAA0101, and found 
that miR-429 was one of the miRNA potentially binding 
KIAA0101 (Fig. 5a). MiR-429 plays an important role in 
EOC metastasis and chemoresistance. In order to vali-
date that KIAA0101 was a direct target gene of miR-429, 
we constructed luciferase reporter plasmid with the wild 
type and mutant KIAA0101 3′-UTR region (Fig. 5b). We 
then co-transfected these plasmids into HEK293T cells 
with miR-429 and control miRNA, respectively. Results 
showed the transfection of miR-429 significantly reduced 
the luciferase activity of wild type KIAA0101 3′-UTR 
reporter, but not mutant KIAA0101 3′-UTR reporter 
(Fig.  5c). Consistently, miR-429 remarkably reduced 
KIAA0101 levels in SKOV3 and COV644 cells (Fig. 5d). 
Furthermore, we found an inverse correlation between 
the expression of KIAA0101 and miR-429 in 40 EOC tis-
sue samples (Fig. 5e). Collectively, these results indicated 
that miR-429 inhibited the expression of KIAA0101 by 
targeting its 3′-UTR region.
MiR‑429 affected EOC cells partially through KIAA0101 
mediated‑Wnt/β‑catenin signaling
Our previous results showed that downregulation of 
KIAA0101 inhibited EOC cell metastasis and Cisplatin 
chemoresistance, KIAA0101 regulates Wnt/β-catenin 
signaling and KIAA0101 was a target of miR-429. It is 
possible that miR-429 exerted its functions on EOC 
cells via KIAA0101 mediated-Wnt/β-catenin signaling 
pathway. If this is the case, then the relief of KIAA0101 
suppression would reverse the regulation of miR-429 
on EOC cells. To test this hypothesis, we simultane-
ously co-transfected plasmids encoding KIAA0101 into 
Fig. 3 Knockdown of KIAA0101 enhances ovarian cancer cell chemosensitivity. a SKOV3 and COV644 cells were cultured in complete medium with 
Cisplatin (8 µM) for 24 h, then medium was changed without Cisplatin for 48 h. The KIAA0101 expression were examined by qRT-PCR at different 
time points indicated. b MTT cell growth rate and c colony formation assays were performed in KIAA0101 knockdown SKOV3 and COV644 cells 
treated with different concentration of Cisplatin indicated. *p < 0.05 compared with siR-Control transfected cells
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miR-429 overexpressing SKOV3 cells. These plasmids did 
not contain the 3′-UTR region of KIAA0101, and were 
therefore resistant to miR-429 regulation. We found that 
while overexpression of miR-429 reduced the expres-
sion of KIAA0101, but co-transfection of KIAA0101-
overexpressing plasmids completely restored the levels of 
KIAA0101 protein as determined by Western blot analy-
sis (Fig.  6a). In these cells, nuclear β-catenin levels and 
TOP flash luciferase activity inhibited by miR-429 over-
expression were partially restored by KIAA0101 overex-
pression (Fig. 6b, c). The decreased expression of Axin2 
and c-myc induced by miR-429 overexpression was par-
tially abrogated by KIAA0101 overexpression (Fig.  6d, 
e). We then performed cell migration and invasion 
assays. As shown in Fig. 7a, b, transfection of KIAA0101-
expressing plasmid partially reversed the inhibition of 
EOC cell metastasis (Fig. 7a, b). Furthermore, reduction 
of cell growth rate induced by miR-429 with Cisplatin 
treatment was partially restored by KIAA0101 (Fig.  7c). 
Together, these data suggested that miR-429 inhibited 
metastasis and chemoresistance of EOC cells, at least in 
part, via KIAA0101 mediated-Wnt/β-catenin signaling 
pathway.
Discussion
In this study, we investigated the role of miR-429 and its 
target gene KIAA0101 in regulation of migration and 
chemoresistance of EOC cell lines, SKOV3 and COV644. 
We found that expression of KIAA0101 was elevated in 
the metastatic EOC tissues, compared to primary EOC 
tissue. Ectopic overexpression of miR-429 showed simi-
lar inhibitory effects as siRNA-mediated depletion of 
KIAA0101 on migration and chemoresistance of EOC 
cells. Mechanistically, we found this inhibitory effects 
were mediated by Wnt/β-catenin signaling pathway. 
Overexpression of miR-429 and depletion of KIAA0101 
significantly suppressed the translocation of β-catenin 
into nucleus.
Fig. 4 KIAA0101 regulates Wnt/β-catenin signaling in EOC cells. a Luciferase activities in SKOV3 and COV644 cells 48 h after co-transfection with 
TOP flash luciferase plasmid and siR-KIAA0101 or siR-Control. b Levels of β-catenin was determined by Western blot in nucleus and cytoplasm of 
SKOV3 and COV644 cells transfected with siR-KIAA0101 or siR-Control. c mRNA and d protein levels of Axin2 and c-myc in SKOV3 and COV644 cells 
transfected with siR-KIAA0101 or siR-Control. *p < 0.05 compared with siR-Control transfected cells
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To our knowledge, this is the first time that we have 
demonstrated KIAA0101 inhibited invasion and resist-
ance to Cisplatin treatment of EOC cells by enhancing 
Wnt/β-catenin signaling. KIAA0101 was initially identi-
fied by the associate factor of PCNA, which is essential 
for the proliferation of normal cells and tumor cells [26]. 
Recent studies have shown the KIAA0101 may serve as 
a biomarker for poor prognosis and recurrence in mul-
tiple human cancers [18, 27]. In this study, we furthered 
revealed that KIAA0101 was also necessary for the 
migration activity and chemoresistance of EOC cells, 
which is mediated by Wnt/β-catenin signaling. Wnt/β-
catenin signaling was reported to play a critical role in 
ovarian tumorigenesis and progression by driving epi-
thelial-to-mesenchymal transition (EMT) [28, 29]. In 
ovarian cancer, Wnt/β-catenin signaling might be acti-
vated by increased expression of β-catenin and glycogen 
synthase kinase 3β (GSK3β), mutations of catenin beta 1 
Fig. 5 KIAA0101 is targeted by miR-429. a The putative binding sites of miR-429 on the KIAA0101 3′-UTR region. b Wild type (WT) of KIAA01013′-
UTR region was mutated. c Luciferase activities in SKOV3 and COV644 cells 48 h after co-transfected with KIAA0101 3′-UTR wild type or mutant 
(Mut) luciferase plasmid and miR-429 or miR-Control. **p < 0.01 compared to miR-Control transfected cells. d Levels of KIAA0101 protein was deter-
mined by Western blot in SKOV3 and COV644 cells transfected with miR-429 or miR-Control. e The correlation of the expression levels of KIAA0101 
and miR-429 in 40 EOC tissue samples (r = −0.648, p < 0.001)
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(CTNNB1) gene, and so on [30, 31]. A recent study has 
also revealed that Wnt/β-catenin signaling maintains 
stem-like properties and promotes resistance to Cispl-
atin and Platinum in high-grade SOC cells [32]. Given 
the role of the Wnt/β-catenin signaling, specific Wnt/
β-catenin signaling inhibitors have generated a great 
amount of enthusiasm in treatment for ovarian cancer 
[28]. Thus, our findings suggest that KIAA0101 may rep-
resent a promising therapeutic target of EOC. However, 
the mechanism by which KIAA0101 regulates Wnt/β-
catenin signaling activity remains to be investigated.
We also found KIAA0101 was directly regulated by 
miR-429. We firstly employed the bioinformatic Target 
Scan tools to predict the miRNA targeting KIAA0101, 
and the binding of miR-429 to the 3′ UTR of KIAA0101 
mRNA was further confirmed by luciferase assay. How-
ever, it is worthy to note that miRNA usually have mul-
tiple targets [33, 34]. In this study, co-transfection of 
KIAA0101 in miR-429 overexpressed EOC cells did 
not fully abrogate the effect of miR-429 overexpression, 
indicating other factors may be involved in this process. 
Further studies are with required to identify other tar-
gets of miR-429 in EOC cells that regulate the process 
of malignancy. Furthermore, miR-429 was found to be 
downregulated in several human cancers [12, 13, 35], 
but upregulation of miR-429 was negatively correlated to 
prognosis of patients with SOC [16], indicating different 
role of miR-429 in regulating cancer progression that are 
initiated from different tissues. In this study, we reported 
the role of miR-429 in regulation of chemoresistance of 
Fig. 6 MiR-429 regulates Wnt/β-catenin signaling pathway partially through KIAA0101. a Levels of KIAA0101 protein was determined by West-
ern blot in SKOV3 cells transfected with miR-429 or miR-Control, together with either vector control or plasmids encoding KIAA0101. b Levels of 
β-catenin was determined by Western blot in nucleus and cytoplasm of SKOV3 cells transfected with miR-429 or miR-Control, together with either 
vector control or plasmids encoding KIAA0101. c Luciferase activities in SKOV3 cells 48 h after transfection with miR-429 or miR-Control, together 
with either vector control or plasmids encoding KIAA0101. d mRNA and e protein levels of Axin2 and c-myc in SKOV3 cells transfected with miR-429 
or miR-Control, together with either vector control or plasmids encoding KIAA0101. *p < 0.05 compared with siR-Control transfected cells
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EOC cells for the first time. The role of miR-429 in regu-
lation of chemoresistance in other cancers may be inves-
tigated in the future.
Conclusions
KIAA0101, targeted by miR-429, promotes invasion and 
chemoresistance of EOC cells through Wnt/β-catenin 
signaling pathway. Both miR-429 and KIAA0101 may be 
used to predict the prognosis of patients with EOCs, and 
may represent new therapeutic targets of EOCs. How-
ever, more investigation needs to be carried out to inves-
tigate how KIAA0101 regulates Wnt/β-catenin signaling, 
and whether targeting miR-429 and/or KIAA0101 is 
capable of suppress EOC progression in vivo.
Fig. 7 MiR-429 affected EOC cells partially through KIAA0101. a Transwell migration assay and b Transwell invasion assays in SKOV3 cells transfected 
with either vector control or plasmids encoding KIAA0101. c MTT cell growth rate was performed in SKOV3 cells transfected with either vector 
control or plasmids encoding KIAA0101, when treated with Cisplatin (8 µM). *p < 0.05 compared with siR-Control transfected cells
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